Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-operative Epirubicin, Capecitabine and Cisplatin in Localised Oesophageal Adenocarcinoma
NCT00220103Phase 2Completed
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Nov 2002
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of epirubicin, capecitabine, cisplatin in oesophageal adenocarcinoma (EAC), sponsored by Royal Marsden NHS Foundation Trust. Started Nov 2002; status: completed.
02
Drugs
epirubicincapecitabinecisplatin
03
Conditions
oesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT00220103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00220103.